Lite Strategy Inc - Company Profile
Powered by 
All the sales intelligence you need on Lite Strategy Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lite Strategy Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lite Strategy Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lite Strategy Inc (Lite Strategy) is a pharmaceutical company focused on developing innovative cancer therapies. The company's main activities include acquiring promising cancer agents and advancing them through clinical development, strategic partnerships, and commercialization. Its major products include Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and Zandelisib, an oral, once-daily, selective PI3Kδ inhibitor. Lite Strategy collaborates with partners like Kyowa Kirin Co Ltd for drug development, although the agreement for Zandelisib was terminated. The company's products are primarily aimed at addressing medical needs in oncology, with applications in treating conditions such as acute myeloid leukemia. Lite Strategy also explores digital asset infrastructure through its Litecoin Treasury Strategy, focusing on financial technology innovation. The company targets global markets, with a focus on enhancing capital efficiency through digital assets. Lite Strategy is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, California, 92121
Website
www.litestrategy.com
Telephone
1 858 3697100
No of Employees
4
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LITS (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-189.7%
(2024 vs 2023)
Market Cap*
$30.5M
Net Profit Margin (2023)
XYZ
141.8%
(2024 vs 2023)
* As of and is in US$
Lite Strategy Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline: | Pharmaceutical research and developments of oncology drug candidates. |
| Voruciclib: Acute Myeloid Leukemia and Solid Tumors | Drug discovery and development |
| ME-344: HER2-Negative Breast Cancer, Colorectal Cancer and Solid Tumors | Cryptocurrency Treasury Management |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In August, the company announced the acquisition of 929,548 Litecoin (LTC) tokens. |
| 2024 | Divestiture | In October, the company sold rights, title and interest in and to certain assets related to ME-344 to Aardvark Therapeutics, Inc. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Anson Funds and Cable Car Capital. |
Competitor Comparison
| Key Parameters | Lite Strategy Inc | Strategy Inc | Arcus Biosciences Inc | Ideaya Biosciences Inc | Semler Scientific Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Tysons Corner | Hayward | South San Francisco | Campbell |
| State/Province | California | Virginia | California | California | California |
| No. of Employees | 4 | 1,539 | 601 | 145 | 79 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frederick W. Driscoll | Chairman | Executive Board | 2024 | 75 |
| Justin File | Chief Executive Officer; Chief Financial Officer; Director | Executive Board | 2025 | 55 |
| James Flynn | Director | Non Executive Board | 2023 | 45 |
| Joshua Riezman | Director | Non Executive Board | 2025 | 42 |
| Nicholas R. Glover, Ph.D. | Director | Non Executive Board | 2013 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer